EIGRQ (Eiger BioPharmaceuticals) Interest Expense : $-2.84 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Eiger BioPharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Eiger BioPharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -1.43 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.84 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Eiger BioPharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ -12.61 Mil. Eiger BioPharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -1.43 Mil. Eiger BioPharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Eiger BioPharmaceuticals Interest Expense Historical Data

The historical data trend for Eiger BioPharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eiger BioPharmaceuticals Interest Expense Chart

Eiger BioPharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-3.41

-3.59

-3.56

-4.13

-5.47

Eiger BioPharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Interest Expense	Get a 7-Day Free Trial															-1.29	-1.34	-1.41	-1.43	-

Eiger BioPharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.84 Mil.

Eiger BioPharmaceuticals (OTCPK:EIGRQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Eiger BioPharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-1.43 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-12.61 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.00 Mil.

Eiger BioPharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Eiger BioPharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Eiger BioPharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eiger BioPharmaceuticals Inc (OTCPK:EIGRQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2155 Park Boulevard, Palo Alto, CA, USA, 94306

Website

https://www.eigerbio.com

Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Executives

Richard A Kayne	10 percent owner
Leen Kawas	10 percent owner	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Ingrid Choong	officer: Chief Business Officer	24645 SUMMERHILL AVE, LOS ALTOS CA 94024
William G Kachioff	officer: CFO	4060 PORTE DE PALMAS, SAN DIEGO CA 92122
James Vollins	officer: General Counsel	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mayer Eldon C. Iii	officer: Ex VP & Chief Commerc. Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Lisa Kelly-croswell	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Thomas John Dietz	director	C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Jeffrey S Glenn	director	350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306
David Apelian	director	C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511
Sriram Ryali	officer: Chief Financial Officer	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Christine Murray	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Erik Atkisson	officer: GC & Chief Compliance Officer	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Kim Sablich	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
David A Cory	director, officer: President and CEO	350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306